Market analysis forecasts the global facial rejuvenation market will reach $5.66 billion by 2030, growing at a 10.2% compound annual growth rate from current levels. The projection encompasses injectables, energy devices, and surgical procedures, reflecting sustained practitioner and patient investment in aesthetic maintenance.
Market
Facial Rejuvenation Market Forecast to Hit $5.66B by 2030
10.2% CAGR projects sustained injectable and device demand through end of decade.
10.2% CAGR through 2030 signals sustained aesthetic spending.
The 10.2% CAGR outpaces general healthcare inflation, signaling that aesthetic spending is structural rather than cyclical. For practice owners, the data supports continued capital deployment into injectables and device infrastructure—particularly in underserved geographies where facial procedures remain underpenetrated. However, the forecast assumes no major disruption from GLP-1 weight-loss drugs or biosimilar toxin pricing compression. Practices should model downside scenarios where toxin unit economics compress further and filler volume shifts toward biostimulators and hybrid protocols.
Source: original report ↗
Frequently asked questions
What will the facial rejuvenation market be worth by 2030?
The global facial rejuvenation market is projected to reach $5.66 billion by 2030, growing at a 10.2% compound annual growth rate. This growth outpaces general healthcare inflation, indicating that aesthetic spending is structural rather than cyclical.
How fast is the facial rejuvenation market growing?
The market is growing at a 10.2% CAGR through 2030, which exceeds typical healthcare inflation rates. This sustained growth reflects ongoing practitioner and patient investment in injectables, energy devices, and surgical procedures.
Should I invest in injectable and device equipment for my medspa?
Yes, the 10.2% CAGR forecast supports continued capital deployment into injectables and device infrastructure, particularly in underserved geographies where facial procedures remain underpenetrated. However, practices should also model downside scenarios where toxin pricing compresses and volume shifts toward biostimulators and hybrid protocols.
What could disrupt the facial rejuvenation market growth forecast?
The forecast assumes no major disruption from GLP-1 weight-loss drugs or biosimilar toxin pricing compression. Practices should prepare for scenarios where toxin unit economics compress further and patient demand shifts toward biostimulators and hybrid treatment protocols.
Is facial rejuvenation spending affected by economic cycles?
No—the 10.2% CAGR outpacing general healthcare inflation signals that aesthetic spending is structural rather than cyclical. This means facial rejuvenation demand is expected to remain resilient across economic conditions through 2030.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.